FDA Advisory Committees Recommend Approval of Indivior ’s RBP-6000 for the Treatment of Opioid Use Disorder

Slough, UK and Richmond, VA, 31 October 2017 – Indivior PLC (LON: INDV) announced today that the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news